Dr. Ghobadi on the Potential Development of CAR T Cells in Solid Tumors

Video

Armin Ghobadi, MD, assistant professor of medicine, Division of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses the potential development of chimeric antigen receptor (CAR) T cells in solid tumors.

Armin Ghobadi, MD, assistant professor of medicine, Division of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses the potential development of chimeric antigen receptor (CAR) T cells in solid tumors.

Although CAR T-cell therapy has made a big impact in hematologic malignancies, researchers need to focus on finding better targets if the therapy is to transition to solid tumor oncology, explains Ghobadi. Currently, CAR T cells target an antigen that is expressed on the surface of the tumor cell. Refinements to the therapy may enable CAR T cells to target an antigen that is not as visible to CAR T cells.

The biggest challenge with solid tumors is the negative inhibitory environment that prevents the function and penetration of CAR T cells in the tumor microenvironment, says Ghobadi. There is a lot of research in that area, such as making CAR T cells resistant against the negative environment or converting a negative inhibitory receptor to a receptor that activates CAR T cells, states Ghobadi.

Recent Videos
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
David Barrett, JD, the chief executive officer of ASGCT
Alfred L. Garfall, MD, MS, associate professor of medicine (hematology-oncology) and director, Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania; and section chief, Multiple Myeloma, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
© 2025 MJH Life Sciences

All rights reserved.